Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.

HIV medicine - 1 Sept 2017

Gallien S, Journot V, Loriot M-A, Sauvageon H, Morlat P, Reynes J, Reliquet V, Chêne G, Molina J-M

Abstract excerpt

OBJECTIVES: Single nucleotide polymorphisms in the cytochrome P450 (CYP) 2B6 gene have been associated with high interindividual variation in efavirenz pharmacokinetics. However, clinical data on the relationship of CYP2B6 polymorphisms with the occurrence of efavirenz-induced central nervous system (CNS) symptoms are limited. METHODS: We analysed four polymorphisms in the CYP2B6 (516 G>T), CYP3A5 (6986 A>G) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzoxazines

Share to Central Nervous System Diseases

Share to Cyclopropanes

Share to Cytochrome P-450 CYP2B6

Share to Drug-Related Side Effects and Adverse Reactions

Share to Plasma

Source

Identifiers

PMID: 28145050
DOI: 10.1111/hiv.12488

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.PMID 28145050Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Semantic proximity Read ↗

Impact of pharmacogenetics on CNS side effects related to efavirenz.Semantic proximity Read ↗

CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil.Semantic proximity Read ↗

Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).Semantic proximity Read ↗

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsSemantic proximity Read ↗

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.Semantic proximity Read ↗

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Semantic proximity Read ↗

Efavirenz in the therapy of HIV infectionSemantic proximity Read ↗

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.Semantic proximity Read ↗

Efavirenz and the CNS: what we already know and questions that need to be answered.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.